Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy... Show more
Biofrontera Inc. is a biopharmaceutical company that develops and commercializes prescription treatments for dermatological conditions caused primarily by sun exposure and skin damage. Listed on the Nasdaq under the ticker BFRI, the company is best known for its photodynamic therapy (PDT) franchise built around the drug Ameluz and its companion light devices. Investors follow Biofrontera because it operates in a specialized niche of dermatology where its drug-device combination offers a differentiated approach to treating pre-cancerous skin lesions and, potentially, certain skin cancers.
Biofrontera Inc. was incorporated in 2015 as a Delaware corporation and is headquartered in Woburn, Massachusetts. The company is the U.S. arm of a broader Biofrontera group with German roots, and it has historically relied on its European parent for manufacturing and licensing before moving to assume fuller control of its U.S. assets.
The company's principal product is Ameluz (aminolevulinic acid hydrochloride), a topical gel used in combination with the BF-RhodoLED and RhodoLED XL lamp series. Together, this drug-device combination delivers photodynamic therapy, or PDT — a treatment in which a light-activated drug accumulates in abnormal skin cells and is then activated by a specific wavelength of light to destroy those cells. In the United States, Ameluz PDT is approved for the lesion-directed and field-directed treatment of actinic keratosis (AK), which are pre-cancerous skin lesions of mild-to-moderate severity on the face and scalp.
Biofrontera previously also marketed Xepi (ozenoxacin cream, 1%), a topical antibiotic used to treat impetigo, a bacterial skin infection. In November 2025, the company announced the sale of its U.S. license for Xepi to Pelthos Therapeutics, refocusing its portfolio on its PDT platform.
Biofrontera operates a specialized commercial model centered on dermatology practices. Ameluz is distributed as a "buy-and-bill" product: dermatologists purchase the drug and lamp device directly, hold them in inventory, and then bill payers when they perform a treatment. This differs from traditional pharmacy distribution and means the company's revenue depends on adoption by dermatology offices and an installed base of RhodoLED lamps. The company markets its products through its own U.S. commercial sales force and focuses on converting dermatologists from traditional cryotherapy toward field-directed PDT treatments.
Within the actinic keratosis market, Biofrontera competes mainly against cryotherapy, which remains the most common treatment, as well as topical medications and other PDT systems such as Levulan with the Blu-U light. The company's differentiation lies in its field-directed approach, which can treat multiple lesions and surrounding sun-damaged skin at once, along with an installed lamp base that supports repeat treatments.
Biofrontera attracts investor attention because of its focused position in a large and recurring dermatology market. Actinic keratosis affects tens of millions of Americans, and sun-damaged skin creates ongoing demand for repeat treatments, which supports recurring product use among dermatology practices. The company has also pursued a broader BFRI growth story through label and pipeline expansion, including efforts to treat actinic keratosis on the trunk and extremities, superficial basal cell carcinoma, and moderate-to-severe acne.
Strategically, the company has worked to strengthen its financial profile by taking fuller control of its U.S. intellectual property and manufacturing rights, which management has described as a way to reduce product costs and improve gross margins. These moves, combined with a drug-device platform that is difficult for generic competitors to replicate easily, underpin the company's long-term positioning.
Investors should weigh several important risks before considering Biofrontera. As a small-cap, early-commercial-stage biopharmaceutical company, it has a limited product portfolio and has reported operating losses, which means its path to sustained profitability depends on continued revenue growth and disciplined cost management.
The company is also highly dependent on a single flagship product, Ameluz, and on adoption by dermatology providers; any shift in physician preference, reimbursement rates, or competitive dynamics could materially affect results. Regulatory risk is another key factor, since label expansions and pipeline approvals require U.S. Food and Drug Administration (FDA) review and are not guaranteed. Finally, the company's business is subject to seasonality, with PDT treatments historically performed more frequently in colder months, which can create quarter-to-quarter revenue variability.
Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. Users can efficiently screen thousands of stocks and ETFs to surface ideas that align with their own investment strategies. Explore the AI Screener to streamline your research and uncover candidates that match your criteria.
Biofrontera Inc. is a niche biopharmaceutical company built around photodynamic therapy for dermatological conditions, anchored by its Ameluz and RhodoLED drug-device combination. Its focused market position, recurring treatment demand, and expanding clinical pipeline distinguish it from many early-stage peers, while its single-product concentration and history of operating losses underscore the risks inherent in the business. For investors interested in specialized dermatology and small-cap biopharmaceuticals, Biofrontera remains a company worth understanding.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Industry PharmaceuticalsGeneric